# Capecitabine + Bevacizumab in Patients With Recurrent Glioblastoma

> **NCT02669173** · PHASE1 · COMPLETED · sponsor: **Case Comprehensive Cancer Center** · enrollment: 12 (actual)

## Conditions studied

- Glioblastoma

## Interventions

- **DRUG:** Capecitabine
- **DRUG:** Bevacizumab

## Key facts

- **NCT ID:** NCT02669173
- **Lead sponsor:** Case Comprehensive Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-10-11
- **Primary completion:** 2025-01-07
- **Final completion:** 2025-01-07
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2026-02-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02669173

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02669173, "Capecitabine + Bevacizumab in Patients With Recurrent Glioblastoma". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT02669173. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*